title: Factor VIII delivery devices in haemophilia A. Barriers and drivers for treatment adherence.
abstract: OBJECTIVE
  To capture the experience of haemophilia A patients with their devices for coagulation factor reconstitution, the barriers for treatment adherence; and to determine their preferences, presenting a new double-chamber syringe (DCS).
  
  
  METHODS
  A cross-sectional research through a supervised survey and a DCS testing session.
  
  
  RESULTS
  Seventy-four (74) patients participated, 50% of them on prophylaxis treatment, and 7 years (median) with their usual treatment (IQR 17.25). In the survey, the DCS received the highest score (75/100, p < 0.001) and it was the most likely to be used in prophylactic treatment (p < 0.001). In the practical testing session (n = 29), 62.1% preferred the DCS, and required 43 seconds as median time (24.5-82) for preparation, vs. 4 minutes (1-15) with their usual treatment (p < 0.001). The favourable opinion of their doctor regarding prophylaxis was very influential on the attitude of participants towards treatment adherence (OR = 1.324, CI 95% = 1.040-1.685, p = 0.023).
  
  
  CONCLUSIONS
  The DCS was the preferred device, and was likely to encourage prophylaxis.
authors.affiliation: Unidad Médica, Pfizer S.L.U.. Isabel.fernandez-arias@pfizer.com.
authors.forename: Isabel
authors.initials: I
authors.lastname: Fernández-Arias
authors.affiliation: Unidad Médica, Pfizer S.L.U.. Hae.KyungKim@pfizer.com.
authors.forename: Hae Kyung
authors.initials: HK
authors.lastname: Kim
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003430:Cross-Sectional Studies; D016503:Drug Delivery Systems; D005169:Factor VIII / Q000008:administration & dosage* / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D013594:Syringes; D055815:Young Adult
chemical_list: D005169:Factor VIII